Can we ensure the safe use of known human teratogens? The iPLEDGE™ test case

Drug Safety

Volumn 30, Issue 1, 2007, Pages 5-15

  Honein, Margaret A ^a,c   Lindstrom, Jill A ^b   Kweder, Sandra L ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CLOZAPINE; CONTRACEPTIVE AGENT; ISOTRETINOIN; THALIDOMIDE;

ACNE VULGARIS; DISEASE CONTROL; DRUG EXPOSURE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG USE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HIGH RISK PREGNANCY; HUMAN; PATIENT COUNSELING; PATIENT SAFETY; PHARMACIST; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REGISTRATION; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TERATOGENICITY; UNITED STATES; WOMEN'S HEALTH;

EID: 33846065096     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730010-00002     Document Type: Review

References (27)

1. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985 Oct 3; 313 (14): 837-41
2. Lammer EJ, Adams J. Testimony before the Dermatologic Drugs Advisory Committee, 2000 Sep 18 [online]. Available at URL: http://www.fda.gov/ohrms/ dockets/ac/00/transcripts/3639t1a.pdf [Accessed 2006 Nov 21]
3. Food and Drug Administration. Proceedings of the FDA Joint Drug Safety and Risk Management & Dermatologic and Ophthalmic Drugs Advisory Committee Meeting, 2004 Feb 26-27; Gaithersburg, MD [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/cder04.html#Dermatologic [Accessed 2006 Nov 21]
4. Honein MA, Paulozzi LJ, Erickson JD. Continued occurrence of Accutane-exposed pregnancies. Teratology 2001 Sep; 64 (3): 142-7
5. Fantel AG, Shepard TH, Newell-Morris LL, et al. Teratogenic effects of retinoic acid in pigtail monkeys (Macaca nemestrina): I. General features. Teratology 1977 Feb; 15 (1): 65-71
6. Kochhar D. Teratogenic activity of retinoic acid. Acta Pathol Microbiol Scand 1967 1967; 70: 398-404
7. Shenefelt RE. Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment. Teratology 1972 Feb; 5 (1): 103-18
8. Leach EE. Testimony before the FDA Dermatologic and Ophthalmic Drugs Advisory Committee meeting, 18 September 2000; Gaithersburg, MD [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/slides/3639s1.htm [Accessed 2006 Dec 11]
9. Honein MA, Moore CA, Erickson JD. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example. Drug Saf 2004; 27 (14): 1069-80
10. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 2005; 141: 563-9
11. Food and Drug Administration. Information on Accutane [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/accutane/default.htm [Accessed 2006 Dec 21]
12. The iPLEDGE programme: guide to best practices for isotretinoin [online; p5]. Available from URL: https://www.ipledgeprogram.com/Documents/ 10266_5_Best%20Practices_Mv10.pdf [Accessed 2006 Dec 11]
13. United States Department of Health and Human Services. 1988 Clinical Laboratories Improvement Amendment. Federal Register: US Government Printing Office. 1990; 55: 9495
14. Robertson J, Polifka JE, Avner M, et al. A survey of pregnant women using isotretinoin. Birth Defects Res A Clin Mol Teratol 2005 Nov; 73 (11): 881-7
15. Avignan M, DalPan G. Overview of the first year of the isotretinoin risk management programme [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/04/briefing/4017B1-06a%20FDA%20Backgrounder-ODS%20Sec%20C%20Tab%202. pdf [Accessed 2006 Jul 14]
16. Pitts M, Karwoski CB. PID D030417 Drug: isotretinoin topic. Pregnancy exposures [online]. Accessed from URL: http://www.fda.gov/ohrms/dockets/ac/04/ briefing/4017B1-06a%20FDA%20Backgrounder-ODS%20Sec%20C%20Tab%203.pdf [Accessed July 14, 2006]
17. Rex JH, Turnbull JE, Allen SJ, et al. Systematic root cause analysis of adverse drug events in a tertiary referral hospital. Jt Comm J Qual Improv 2000 Oct; 26 (10): 563-75
18. Neily J, Ogrinc G, Mills P, et al. Using aggregate root cause analysis to improve patient safety. Jt Comm J Qual Saf 2003 Aug; 29 (8): 434-9, 381
19. How root-cause analysis can improve patient safety. Qual Lett Healthc Lead Oct 2001 Oct; 13 (10): 2-12
20. Mitchell AA, Van Bennekom CM. Survey of Accutane use in women. Briefing materials provided to the FDA Dermatologic and Ophthalmic Drugs Advisory Committee, 8/28/2000 [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/00/slides/3639s1i.ppt [Accessed 2006 Dec 11]
21. Karwoski CB. Practical experience with risk management in the US [online]. Available from URL: http://www.fda.gov/cder/present/DIA2006/Karwoski. pdf [Accessed 2006 Dec 1]
22. Boodman SG. Too hard to take: a strict new acne drug programme may prevent birth defects. But many complain it also drives people away from a potentially life-transforming treatment. Washingtonpost.com, 2006 Sep 5
23. US FDA Drug Safety and Risk Management Advisory Committee Meeting, 10 February 2006 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/ 06/slides/2006-4202_slide-index-02-10.htm [Accessed 2006 Nov 28]
24. Daniel KL, Honein MA, Moore CA. Sharing prescription medication among teenage girls: potential danger to unplanned/ undiagnosed pregnancies. Pediatrics 2003 May; 111 (5 Part 2): 1167-70
25. Food and Drug Administration (FDA). FDA announces enhancement to isotretinoin risk management program [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01328.html [Accessed 2006 Dec 1]
26. Petrini J, Damus K, Russell R, et al. Contribution of birth defects to infant mortality in the United States. Teratology 2002; 66 Suppl. 1: S3-6
27. Yoon PW, Olney RS, Khoury MJ, et al. Contribution of birth defects and genetic diseases to pediatric hospitalizations: a population-based study. Arch Pediatr Adolesc Med 1997 Nov; 151 (11): 1096-103